FDA Grants Full Approval to Tivdak for Treating Recurrent or Metastatic Cervical Cancer Patients Experiencing Disease Progression After Chemotherapy

Approval of Tivdak was based on promising results from a Phase III innovaTV 301 clinical trial, which demonstrated a 30% reduction in the risk of death in patients with recurrent or metastatic cervical cancer.